Identification of a Novel BRAF Thr599dup Mutation in Lung Adenocarcinoma

BRAF mutations are known as oncogenic drivers of non-small cell lung cancer (NSCLC). BRAF inhibition has demonstrated anti-tumor activity in patients with BRAF V600E mutant NSCLC. Further molecular screening for novel BRAF thr599dup mutation is warranted. The novel BRAF Thr599dup gene mutation, for...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhang, Xuefei, Li, Mo, Lv, Desheng, Sun, Ge, Bai, Yu, Tian, Hui, Liu, Changhong
Formato: Online Artículo Texto
Lenguaje:English
Publicado: De Gruyter Open 2018
Materias:
Regular Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046617/
https://www.ncbi.nlm.nih.gov/pubmed/30019008
http://dx.doi.org/10.1515/med-2018-0042

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6046617/
https://www.ncbi.nlm.nih.gov/pubmed/30019008
http://dx.doi.org/10.1515/med-2018-0042

Ejemplares similares